GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
STAMFORD, Conn.--(BUSINESS WIRE)--Aug. 9, 2024--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that, effective as of June 26, 2024, the compensation committee of GeneDx's board of directors granted seven newly hired employees 75,100 restricted stock units ("RSUs") as inducements material to each employee entering into employment with GeneDx. The RSUs were granted under GeneDx's 2023 Equity Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).
2024年8月9日--康涅狄格州斯坦福--(BUSINESS WIRE)--GeneDx (納斯達克: WGS)是通過基因組洞見提供改進健康成果的領導者，今天宣佈，自2024年6月26日起，GeneDx的董事會的薪酬委員會授予七名新員工75,100個限制性股票單位(RSUs)，作爲每個進入GeneDx僱傭的員工的誘因資料。這些RSU是根據GeneDx的2023年股權誘因計劃授予的，並符合納斯達克上市規則5635(c)(4)。
The inducement RSUs will vest in equal annual installments over the four-year period following the grant date, subject to the employee's continued service with the Company on each applicable vesting date.
誘因RSUs將在授予日後的四年內平均每年分期歸屬，前提是員工在每個可適用的歸屬日繼續在公司服務。
Each RSU represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement. Typically, upon full vesting, shares are sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs and funded by a "sell to cover" transaction. This does not represent a discretionary transaction by the Reporting Person.
每個RSU代表了一項在結算時有條件獲得發行人A類普通股1股的權利。通常，在完全歸屬時，股票會被出售以支付與RSUs的歸屬和結算相關的稅款保留義務，而這些股票由"賣出以支付"交易資助。此舉不代表舉報人的自由裁量權。
About GeneDx
關於GeneDx
At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world's largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It all starts with a single test. For more information, please visit genedx.com and connect with us on LinkedIn, X, Facebook, and Instagram.
在GeneDx (納斯達克:WGS) ,我們認爲每個人都應該得到個性化的、有針對性的醫療保健——而這一切都始於基因診斷。受世界上最大的罕見病數據集之一的推動，我們行業領先的外顯子組和基因組測試將複雜的基因組數據轉化爲臨床答案，從而解鎖個性化健康計劃，加速藥物發現，並提高衛生系統效率。這一切都始於一次簡單的測試。欲了解更多信息，請訪問genedx.com，並通過 LinkedIn 、X、Facebook和Instagram與我們聯繫。
View source version on businesswire.com:
請查看商業線(businesswire.com)的源版本。
Investor Relations Contact:
investors@GeneDx.com
投資者關係聯繫人：
investors@GeneDx.com
Media Contact:
press@GeneDx.com
媒體聯繫人：
press@GeneDx.com
Source: GeneDx
來源：GeneDx